Candidate gene mutation analysis in idiopathic acquired sideroblastic anemia (refractory anemia with ringed sideroblasts)

Leukemia Research

Volumn 31, Issue 5, 2007, Pages 623-628

  Steensma, David P ^a   Hecksel, Kathleen A ^a   Porcher, Julie C ^a   Lasho, Terra L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Erythropoietic protoporphyria; Ferrochelatase; Mutation analysis; Sideroblastic anemia

Indexed keywords

FERROCHELATASE; FERROUS ION; HEME; MESSENGER RNA; PROTOPORPHYRIN;

ABCB7 GENE; ARTICLE; CATALYSIS; CLINICAL ARTICLE; ENZYME ACTIVITY; ERYTHROPOIETIC PROTOPORPHYRIA; FECH GENE; GENE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HEME SYNTHESIS; HUMAN; HUMAN TISSUE; MISSENSE MUTATION; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PUS1 GENE; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; SIDEROBLASTIC ANEMIA; SOMATIC MUTATION;

ANEMIA, REFRACTORY; ANEMIA, SIDEROBLASTIC; ATP-BINDING CASSETTE TRANSPORTERS; BONE MARROW; CELLS, CULTURED; ERYTHROBLASTS; ERYTHROCYTES; ERYTHROID PROGENITOR CELLS; FERROCHELATASE; HUMANS; HYDRO-LYASES; POINT MUTATION; PROTOPORPHYRINS;

EID: 34147171967     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.06.005     Document Type: Article

References (58)

1. Alcindor T., and Bridges K.R. Sideroblastic anemias. Br J Hematol 116 4 (2002) 733-743
2. Bjorkman S.E. Chronic refractory anemia with sideroblastic bone marrow: a study of four cases. Blood 11 (1956) 250-259
3. Bennett J.M., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Hematol 51 2 (1982) 189-199
4. Vardiman J.W., Harris N.L., and Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100 7 (2002) 2292-2302
5. Yoshida Y., et al. Diagnostic and biological significance of sideroblastic erythropoiesis in the myelodysplastic syndromes. Int J Hematol 67 2 (1998) 137-144
6. Cazzola M. Ring sideroblasts and myelodysplastic syndromes. J Clin Pathol 36 12 (1983) 1413-1414
7. Garand R., et al. Heterogeneity of acquired idiopathic sideroblastic anemia (AISA). Leuk Res 16 5 (1992) 463-468
8. Gattermann N., Aul C., and Schneider W. Two types of acquired idiopathic sideroblastic anemia (AISA). Br J Hematol 74 1 (1990) 45-52
9. Bottomley S.S. Congenital sideroblastic anemias. Curr Hematol Rep 5 1 (2006) 41-49
10. Fleming M.D. The genetics of inherited sideroblastic anemias. Semin Hematol 39 4 (2002) 270-281
11. Cotter P.D., et al. Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts [see comment]. J Clin Invest 96 4 (1995) 2090-2096
12. Cazzola M., et al. Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. Blood 96 13 (2000) 4363-4365
13. Harigae H., et al. A novel mutation of the erythroid-specific gamma-aminolevulinate synthase gene in a patient with non-inherited pyridoxine-responsive sideroblastic anemia. Am J Hematol 62 2 (1999) 112-114
14. Cortesao E., et al. Onset of X-linked sideroblastic anemia in the fourth decade. Hematologica 89 10 (2004) 1261-1263
15. Bekri S., et al. A promoter mutation in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causes X-linked sideroblastic anemia. Blood 102 2 (2003) 698-704
16. Furuyama K., et al. Late-onset X-linked sideroblastic anemia following hemodialysis. Blood 101 11 (2003) 4623-4624
17. Cotter P.D., et al. Four new mutations in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causing X-linked sideroblastic anemia: increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis. Blood 93 5 (1999) 1757-1769
18. Furuyama K., and Sassa S. Multiple mechanisms for hereditary sideroblastic anemia. Cell Mol Biol (Noisy-le-grand) 48 1 (2002) 5-10
19. Steensma D.P., Gibbons R.J., and Higgs D.R. Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood 105 2 (2005) 443-452
20. Nakahashi Y., et al. The molecular defect of ferrochelatase in a patient with erythropoietic protoporphyria. Proc Natl Acad Sci USA 89 1 (1992) 281-285
21. Magnus I.A., et al. Erythropoietic protoporphyria. A new porphyria syndrome with solar urticaria due to protoporphyrinaemia. Lancet 2 (1961) 448-451
22. Todd D.J. Erythropoietic protoporphyria. Br J Dermatol 131 6 (1994) 751-766
23. Bloomer J., et al. Molecular defects in ferrochelatase in patients with protoporphyria requiring liver transplantation. J Clin Invest 102 1 (1998) 107-114
24. Rademakers L.H., et al. Accumulation of iron in erythroblasts of patients with erythropoietic protoporphyria. Eur J Clin Invest 23 2 (1993) 130-138
25. Aplin C., et al. Late-onset erythropoietic porphyria caused by a chromosome 18q deletion in erythroid cells. J Invest Dermatol 117 6 (2001) 1647-1649
26. Takeda Y., et al. Erythropoietic protoporphyria without cutaneous photosensitivity and with ringed sideroblasts in an atomic bomb survivor. Lancet 347 8998 (1996) 395-396
27. Shirota T., et al. Myelodysplastic syndrome terminating in erythropoietic protoporphyria after 15 years of aplastic anemia. Int J Hematol 72 1 (2000) 44-47
28. Lim H.W., et al. Photosensitivity, abnormal porphyrin profile, and sideroblastic anemia. J Am Acad Dermatol 27 2 Pt 2 (1992) 287-292
29. Goodwin R.G., et al. Photosensitivity and acute liver injury in myeloproliferative disorder secondary to late-onset protoporphyria caused by deletion of a ferrochelatase gene in hematopoietic cells. Blood 107 1 (2006) 60-62
30. Rothstein G., Lee R., and Cartwright G.E. Sideroblastic anemia with dermal photosensitivity and greatly increased erythrocyte protoporphyrin. New Engl J Med 280 11 (1969) 587-590
31. Takeda Y., et al. Acquired hypochromic and microcytic sideroblastic anemia responsive to pyridoxine with low value of free erythrocyte protoporphyrin: a possible subgroup of idiopathic acquired sideroblastic anemia (IASA). Br J Hematol 90 1 (1995) 207-209
32. Lee G.R., Cartwright G.E., and Wintrobe M.M. The response of free erythrocyte protoporphyrin to pyridoxine therapy in a patient with sideroachrestic (sideroblastic) anemia. Blood 27 4 (1966) 557-567
33. Bottomley S.S. Porphyrin and iron metabolism in sideroblastic anemia. Semin Hematol 14 2 (1977) 169-185
34. Romslo I., et al. Sideroblastic anemia with markedly increased free erythrocyte protoporphyrin without dermal photosensitivity. Blood 59 3 (1982) 628-633
35. Pasanen A.V., et al. Haem biosynthesis in refractory sideroblastic anemia associated with the preleukaemic syndrome. Scand J Hematol 27 1 (1981) 35-44
36. Jaffe E.S., et al. WHO classification: tumours of haematopoietic and lymphoid tissues (2001), International Agency For Research on Cancer (IARC) Press, Lyon
37. Rufenacht U.B., et al. Rapid molecular diagnosis of erythropoietic protoporphyria among Swiss patients. Clin Chem Lab Med 36 10 (1998) 763-765
38. Di Pierro E., et al. A point mutation affecting an SP1 binding site in the promoter of the ferrochelatase gene impairs gene transcription and causes erythropoietic protoporphyria. Exp Hematol 33 5 (2005) 584-591
39. Gouya L., et al. Mutations in the ferrochelatase gene of four Spanish patients with erythropoietic protoporphyria. J Invest Dermatol 111 3 (1998) 406-409
40. Chen F.P., et al. Ferrochelatase gene mutations in erythropoietic protoporphyria: focus on liver disease. Cell Mol Biol (Noisy-le-grand) 48 1 (2002) 83-89
41. Steensma D.P., et al. Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations. Blood 103 6 (2004) 2019-2026
42. Steensma D.P., and Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res 27 2 (2003) 95-120
43. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29 9 (2001) e45
44. Ford R.E., and Ellefson R.D. Quantitation of erythrocyte protoporphyrins and zinc protoporphyrin by high-pressure liquid chromatography. Clin Chem 30 (1984) 972
45. Gouya L., et al. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat Genet 30 1 (2002) 27-28
46. Risheg H., Chen F.P., and Bloomer J.R. Genotypic determinants of phenotype in North American patients with erythropoietic protoporphyria. Mol Genet Metab 80 1-2 (2003) 196-206
47. Whatley S.D., et al. Autosomal recessive erythropoietic protoporphyria in the United Kingdom: prevalence and relationship to liver disease. J Med Genet 41 8 (2004) e105
48. Pellagatti A., et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon stimulated genes and correlation to FAB subtype and karyotype. Blood (2006)
49. Shin M.G., et al. Mitochondrial DNA mutations in patients with myelodysplastic syndromes. Blood 101 8 (2003) 3118-3125
50. Gattermann N., Aul C., and Schneider W. Is acquired idiopathic sideroblastic anemia (AISA) a disorder of mitochondrial DNA?. Leukemia 7 12 (1993) 2069-2076
51. May A., Al-Sabah A.I., and Lawless S.L. Abstract 3542: acquired sideroblastic anemia unresponsive to pyridoxine caused by a somatic mutation in ALA synthase 2. Blood 106 11 (2005)
52. Cazzola M., et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood 101 5 (2003) 1996-2000
53. Tehranchi R., et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood 106 1 (2005) 247-253
54. Matthes T.W., et al. Increased apoptosis in acquired sideroblastic anemia. Br J Hematol 111 3 (2000) 843-852
55. Pellagatti A., et al. Gene expression profiling in the myelodysplastic syndromes using cDNA microarray technology. Br J Hematol 125 5 (2004) 576-583
56. Wang X., et al. Erythropoietic protoporphyria: four novel frameshift mutations in the ferrochelatase gene. J Invest Dermatol 109 5 (1997) 688-691
57. Todd D.J., et al. Identification of a single base pair deletion (40 del G) in exon 1 of the ferrochelatase gene in patients with erythropoietic protoporphyria. Hum Mol Genet 2 9 (1993) 1495-1496
58. den Dunnen J.T., and Antonarakis S.E. Nomenclature for the description of human sequence variations. Hum Genet 109 1 (2001) 121-124